We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+19.81%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.35B
AUM Growth
+$99.6M
Cap. Flow
-$51.8M
Cap. Flow %
-3.83%
Top 10 Hldgs %
51.22%
Holding
199
New
40
Increased
30
Reduced
31
Closed
45

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$43.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
3
BAX icon
Baxter International
BAX
+$15.5M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$11.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$22.7M
2
RLYP
RELYPSA INC COM
RLYP
+$18.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$17.6M
4
CEMP
Cempra, Inc.
CEMP
+$16.2M
5
SHPG
Shire pic
SHPG
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 86%
2 Consumer Discretionary 0.08%
3 Financials 0.04%
4 Consumer Staples 0.02%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIL
101
DELISTED
Trillium Therapeutics Inc.
TRIL
$378K 0.03%
30,000
– –
AKAO
102
DELISTED
Achaogen Inc
AKAO
$344K 0.03%
60,000
– –
APYX icon
103
Apyx Medical
APYX
$162M
$342K 0.03%
162,700
– –
ARIA
104
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$313K 0.02%
50,000
-400,000
-89% -$2.63M
ARMP icon
105
Armata Pharmaceuticals
ARMP
$168M
$298K 0.02%
534
-37
-6% -$28.3K
TNDM icon
106
Tandem Diabetes Care
TNDM
$1.27B
$295K 0.02%
+2,500
New +$248K
CRIS icon
107
Curis
CRIS
$9.71M
$291K 0.02%
50
– –
CRL icon
108
Charles River Laboratories
CRL
$11.3B
$274K 0.02%
+3,410
New +$246K
HNT
109
DELISTED
HEALTH NET INC
HNT
$262K 0.02%
3,831
– –
GTS
110
DELISTED
Triple-S Management Corporation
GTS
$254K 0.02%
11,147
– –
GILD icon
111
Gilead Sciences
GILD
$165B
$249K 0.02%
2,457
– –
PMC
112
DELISTED
PharMerica Corporation
PMC
$238K 0.02%
6,800
– –
MCK icon
113
McKesson
MCK
$104B
$233K 0.02%
+1,179
New +$223K
ITGR icon
114
Integer Holdings
ITGR
$3.39B
$231K 0.02%
4,817
– –
TARO
115
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$231K 0.02%
1,493
– –
CRVL icon
116
CorVel
CRVL
$3.18B
$225K 0.02%
+15,345
New +$189K
CBM
117
DELISTED
Cambrex Corporation
CBM
$221K 0.02%
4,692
– –
COR icon
118
Cencora
COR
$62B
$211K 0.02%
+2,030
New +$199K
THC icon
119
Tenet Healthcare
THC
$22.2B
$210K 0.02%
+6,927
New +$227K
LPNT
120
DELISTED
LifePoint Health, Inc.
LPNT
$210K 0.02%
2,862
+340
+13% +$24.2K
MGLN
121
DELISTED
Magellan Health Services, Inc.
MGLN
$207K 0.02%
3,351
-59
-2% -$3.17K
WOOF
122
DELISTED
VCA Inc.
WOOF
$205K 0.02%
+3,731
New +$205K
SCAI
123
DELISTED
Surgical Care Affiliates, Inc.
SCAI
$204K 0.02%
+5,133
New +$179K
BIIB icon
124
Biogen
BIIB
$30.9B
$199K 0.01%
+648
New +$186K
ENSG icon
125
The Ensign Group
ENSG
$10.6B
$198K 0.01%
+9,347
New +$197K
3 4
5
6 7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Perceptive Advisors held 199 positions worth $1.35B, up 8% from $1.25B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $51.8M in Q4 2015, closing 45 positions and reducing 31 holdings. Its most notable exit was RELYPSA INC COM, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Perceptive Advisors opened a new position in Allergan plc worth $45.3M.

  • Perceptive Advisors's largest Q4 2015 buy was Allergan plc: 145,000 shares worth $45.3M.
  • Perceptive Advisors added most to Teva Pharmaceuticals in Q4 2015, an estimated $19.8M increase.
  • Perceptive Advisors's biggest Q4 2015 reduction was Neurocrine Biosciences, cutting an estimated $22.7M.
  • Perceptive Advisors fully exited RELYPSA INC COM in Q4 2015, selling an estimated $18.3M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $1.35B portfolio in Q4 2015.
  • Perceptive Advisors opened 40 new positions and closed 45 in Q4 2015.
  • Perceptive Advisors's portfolio value rose 8% quarter-over-quarter to $1.35B.

Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.